Rebekkah McGronan
Family · Elizabeth City, NCNPI 1821609603
Payments from drug & device makers
Across 102 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$350
- AbbVie$235
- Novartis$133
- Lilly USA, LLC$121
- Pfizer$119
- Otsuka America Pharmaceutical, Inc.$118
- plus $712 from 18 others
What the payments were for
- Food & beverage$1,788100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $350 |
| AbbVie | 12 | $235 |
| Novartis | 8 | $133 |
| Lilly USA, LLC | 7 | $121 |
| Pfizer | 6 | $119 |
| Otsuka America Pharmaceutical, Inc. | 5 | $118 |
| Idorsia Pharmaceuticals US Inc | 6 | $93 |
| Amgen | 6 | $90 |
| Astellas Pharma US Inc | 3 | $63 |
| Phathom Pharmaceuticals, Inc. | 3 | $47 |
| Exact Sciences | 2 | $44 |
| Boehringer Ingelheim | 3 | $43 |
| Johnson & Johnson | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 3 | $37 |
| Corcept Therapeutics | 2 | $37 |
| GSK | 2 | $35 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Irhythm Technologies, Inc. | 1 | $28 |
| Verona Pharma, Inc. | 1 | $24 |
| OWP Pharmaceuticals, Inc. | 1 | $24 |
| Corium, LLC | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Mylan Specialty L.p. | 1 | $16 |
How this compares
$1,788 in reported general payments places this provider in the 80th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 23 | $50,877 |
| TrulicityDulaglutide | 21 | $32,065 |
| EliquisApixaban | 36 | $30,736 |
| JardianceEmpagliflozin | 25 | $24,160 |
| FarxigaDapagliflozin Propanediol | 24 | $22,042 |
| MounjaroTirzepatide | 17 | $19,611 |
| XareltoRivaroxaban | 16 | $15,185 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $14,222 |
| EntrestoSacubitril/Valsartan | 11 | $12,394 |
| TradjentaLinagliptin | 16 | $10,964 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 18 | $9,351 |
| Effexor XrVenlafaxine Hcl | 12 | $7,229 |
| MyrbetriqMirabegron | 13 | $5,634 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 48 | $1,386 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,303 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $121 | $51,67638 claims |
| Novo NordiskOzempic | $350 | $50,87723 claims |
| PfizerEliquis, Effexor Xr | $119 | $37,96548 claims |
| Boehringer IngelheimJardiance, Tradjenta | $43 | $35,12541 claims |
| Johnson & JohnsonXarelto | $39 | $15,18516 claims |
| GSKTrelegy Ellipta | $35 | $14,22212 claims |
| NovartisEntresto | $133 | $12,39411 claims |
| Astellas Pharma US IncMyrbetriq | $63 | $5,63413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,522 family providers in North Carolina.
Other family in Elizabeth City
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.